研究概要
一项双盲、安慰剂对照临床试验纳入了 80 名 55 岁以上的健康老年人,其中 40 名男性和 40 名女性,他们在埃及已知的 ILI 季节性(发病高峰)期间接受了安慰剂或 Biobran/MGN-3(500 mg/day)治疗 3 个月。
中文摘要
流感样疾病(ILI)仍是导致老年人严重发病和死亡的重要原因。衰老会降低机体感知病原体以及有效启动先天和适应性免疫应答的能力,因此亟需开发具有保护作用的营养保健品。Biobran/MGN-3是一种来源于米糠的阿拉伯木聚糖,具有显著抗衰老和免疫调节作用,可能有助于预防ILI。本研究评估Biobran/MGN-3对ILI发生率、自然杀伤(NK)细胞活性,以及RIG-1(视黄酸诱导基因1)、MDA5(黑色素瘤分化相关蛋白5)及其下游信号基因ISG-15(干扰素刺激基因15)和MX1(黏液病毒/流感抗性1,干扰素诱导)的影响。在埃及ILI高发季节开展一项双盲、安慰剂对照临床试验,纳入80名55岁以上健康老年人(男女各40名),随机接受安慰剂或Biobran/MGN-3(每日500毫克),连续3个月。依据世卫组织病例定义标准临床确认ILI。所有受试者均评估血液学、肝脏和肾脏指标;每组随机选取6人,通过脱颗粒试验检测NK和NKT(自然杀伤T)细胞活性。研究还使用流式细胞术,在BEAS-2B肺上皮细胞中检测Biobran/MGN-3对RIG-1、MDA5及下游ISG15和MX1的影响。Biobran/MGN-3组ILI发生率和发病密度分别为5.0%和每1000人日0.57例;安慰剂组分别为22.5%和每1000人日2.95例。此外,Biobran/MGN-3摄入显著提高NK活性,较基线和安慰剂组均有改善;并显著上调人肺上皮BEAS-2B细胞系中的RIG-1、MDA5、ISG15和MX1表达。未观察到副作用。综上,Biobran/MGN-3补充剂通过增强NK活性,提高老年受试者先天免疫应答,并降低ILI发生率;同时可上调肺上皮细胞培养物中的RIG-1、MDA5、ISG15和MX1。Biobran/MGN-3可能成为预防多种呼吸道病毒感染的新药物,值得进一步研究。
展开英文摘要原文
Influenza-like illness (ILI) remains a major cause of severe mortality and morbidity in the elderly. Aging is associated with a decreased ability to sense pathogens and mount effective innate and adaptive immune responses, thus mandating the development of protective nutraceuticals. Biobran/MGN-3, an arabinoxylan from rice bran, has potent anti-aging and immunomodulatory effects, suggesting that it may be effective against ILI. The objective of the current study was to investigate the effect of Biobran/MGN-3 on ILI incidence, natural killer (NK) cell activity, and the expressions of RIG-1 (retinoic acid-inducible gene 1), MDA5 (melanoma differentiation-associated protein 5), and their downstream signaling genes ISG-15 (interferon-stimulated genes 15) and MX1 (myxovirus (influenza) resistance 1, interferon-inducible). A double-blind, placebo-controlled clinical trial included eighty healthy older adults over 55 years old, 40 males and 40 females, who received either a placebo or Biobran/MGN-3 (500 mg/day) for 3 months during known ILI seasonality (peak incidence) in Egypt. The incidence of ILI was confirmed clinically according to the WHO case definition criteria. Hematological, hepatic, and renal parameters were assessed in all subjects, while the activity of NK and NKT (natural killer T) cells was assessed in six randomly chosen subjects in each group by the degranulation assay. The effect of Biobran/MGN-3 on RIG-1 and MDA5, as well as downstream ISG15 and MX1, was assessed in BEAS-2B pulmonary epithelial cells using flow cytometry. The incidence rate and incidence density of ILI in the Biobran/MGN-3 group were 5.0% and 0.57 cases per 1000 person-days, respectively, compared to 22.5% and 2.95 cases per 1000 person-days in the placebo group. Furthermore, Biobran/MGN-3 ingestion significantly enhanced NK activity compared to the basal levels and to the placebo group. In addition, Biobran/MGN-3 significantly upregulated the expression levels of RIG-1, MDA5, ISG15, and MX1 in the human pulmonary epithelial BEAS-2B cell lines. No side effects were observed. Taken together, Biobran/MGN-3 supplementation enhanced the innate immune response of elderly subjects by upregulating the NK activity associated with reduction of ILI incidence. It also upregulated the intracellular RIG-1, MDA5, ISG15, and MX1 expression in pulmonary epithelial tissue cultures. Biobran/MGN-3 could be a novel agent with prophylactic effects against a wide spectrum of respiratory viral infections that warrants further investigation.
论文信息
- 作者
- Elsaid AF、Agrawal S、Agrawal A、Ghoneum M
- 第一作者单位
- Department of Community Medicine and Public Health, Zagazig University, Zagazig 44519, Egypt.Egypt
- 通讯作者单位
- Department of Surgery, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.United States
- 文献类型
- 随机对照试验
- 期刊
- Nutrients2021 Nov 19